35 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... First Episode of Opportunistic ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... First Episode of Opportunistic ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA Treatment of Necrotizing Infections of the Skin, Fascia, and Muscle
 • Mixed infections
 • Streptococcus
IDSA Treatment of ... fasciitis #Skin #IDSA ... #Treatment #management ... #antibiotics #pharmacology
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... Potential Treatment ... infection Episode #Pharmacology ... CDifficile #IDSA2017 #Adjunct ... #Antibiotics
Parenteral Antimicrobial Treatment of Common Microorganisms Causing Native Vertebral Osteomyelitis - IDSA 
Staphylococci, oxacillin susceptible
Staphylococci, oxacillin
Antimicrobial Treatment ... Osteomyelitis - IDSA ... Parenteral #IV #Antibiotics ... #pharmacology # ... idsa
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA Recommendations ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
Outpatient Treatment of with Community-Acquired Pneumonia (CAP)
No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa:
Outpatient Treatment ... fluoroquinolone #IDSA ... Acquired #Pneumonia #Antibiotics ... #Treatment #Regimen ... Management #Guidelines #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
IDSA Recommendations ... Trypanosomiasis #IDSA ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... candida #mucosal #IDSA ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology